Clinical trials: Neoadjuvant
Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
In this study, patients with BCC will be given neoadjuvant treatment with a drug called sonidegib. Sonidegib is a daily tablet usually given for BCC that cannot be removed by surgery or that has spread through the body.
- Conditions
- Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer, Invasive Carcinoma
- Trial name
- SONIB (NCT03534947)
- Testing
- Sonidegib, Imiquimod, Surgery
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Melanoma Institute Australia
Myelodysplastic Syndrome
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients
Allogeneic blood stem cell transplant remains the only potential curative treatment for myelodysplastic syndromes (MDS) to date.
- Trial name
- NCT01333449
- Testing
- Decitabine
- Where
- Singapore
- Volunteers
- 6 people
- Sponsor
- Singapore General Hospital
Colon Cancer
ctDNA and TEP Levels in Colon Cancer
This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic…
- Trial name
- NCT07701408
- Testing
- Additional Peripheral Venous Blood Sampling for ctDNA and TEP Biomarker Analysis
- Where
- Slovenia
- Volunteers
- 80 people
- Sponsor
- Institute of Oncology Ljubljana
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Cholangiocarcinoma
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for borderline resectable cholangiocarcinoma.
- Trial name
- NCT03603834
- Testing
- mFOLFOXIRI
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Khon Kaen University
Sebaceous Gland Carcinoma
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant therapy with Sintilimab combined with Disitamab Vedotin in patients with locally advanced, resectable or potentially resectable sebaceous gland…
- Trial name
- NCT07740993
- Testing
- Sintilimab, disitamab vedotin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
Metastatic Colorectal Cancer
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
Colorectal Cancer ranks third among the most frequent malignancies representing a leading cause of cancer-related death worldwide.
- Trial name
- Bohème (NCT05412706)
- Testing
- Niraparib
- Sponsor
- Ospedale Policlinico San Martino
Colon Cancer
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Trial name
- NCT03426904
- Testing
- Neoadjuvant FOLFOX, Conventional adjuvant FOLFOX
- Where
- 4 sites in South Korea
- Volunteers
- 708 people
- Sponsor
- Kyungpook National University Hospital
Non Small Cell Lung Cancer
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
- Trial name
- NCT00986284
- Testing
- gefitinib
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Early or Locally Advanced HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive…
- Trial name
- Neo-Healer (NCT06747338)
- Testing
- KN026, HB1801, Pertuzumab
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Shanghai JMT-Bio Inc.
Prostate Cancer
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of androgens made by the body.
- Trial name
- DART (NCT00651326)
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 13 sites in Canada
- Volunteers
- 48 people
- Sponsor
- NCIC Clinical Trials Group
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT06124378
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Prostate Cancer
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses testosterone) given prior to surgery can decrease the chance that cancer will come back compared to degarelix alone.
- Trial name
- Neo-Red-P (NCT04301414)
- Testing
- BMS-986218 and Degarelix, Degarelix
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Columbia University
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses) and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib, cisplatin and radiation in the locally advanced…
- Trial name
- NCT00627835
- Testing
- sorafenib, sorafenib and cisplatin
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Rectal Adenocarcinoma
Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
The purpose of the study is to evaluate the efficacy and safety of the combination of cytotoxic chemotherapy (Oxaliplatin and 5Fu) with bevacizumab concomitantly with radiotherapy as neoadjuvant treatment for patients with…
- Trial name
- New Beat (NCT01554059)
- Testing
- Bevacizumab, Oxaliplatin, 5-FU
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
The goal of this multicenter retrospective cohort study is to evaluate the impact of different pathological regression types on survival and recurrence patterns, with a particular focus on ypT0N+ patients in patients with…
- Trial name
- NCT06241079
- Testing
- non-intervention
- Volunteers
- 582 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer (NSCLC), Neoadjuvant Immunotherapy
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
- Trial name
- NCT06926179
- Testing
- neoadjuvant immunotherapy
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
- Trial name
- NCT04888546
- Testing
- Anlotinib hydrochloride capsules＋ TQB2450 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction
The main clinical goal of NAC is to down-stage the primary tumor for BCS,yet BCS after NAC has been associated with significantly higher ipsilateral breast tumor recurrences.The accuracy of breast tumor excision in BCS can…
- Trial name
- BCSMANC (NCT01917578)
- Testing
- Ultrasound, CNB, BCS, Modified Radical Mastectomy
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre